<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688711</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-17145</org_study_id>
    <nct_id>NCT03688711</nct_id>
  </id_info>
  <brief_title>Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety
      of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes
      mellitus (T1DM) compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">March 11, 2019</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to plasma glucose recovery.</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue IV glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose recovery after trial drug injection</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose recovery (patient has achieved increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L)) within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial drug injection without administration of rescue IV glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose changes from baseline</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose changes from baseline at 30 minutes, at 20 minutes, at 15 minutes, and at 10 minutes after trial drug injection or at the time of rescue (patient level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to target</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue IV glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area under the effect curve</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes, AUE0-30min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration curve</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Area under the drug concentration curve (AUC) from time zero to 90 minutes, AUC0-90min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum plasma concentration</measure>
    <time_frame>0-120 minutes after dosing</time_frame>
    <description>Maximum plasma drug concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to maximum plasma concentration</measure>
    <time_frame>0-120 minutes after dosing</time_frame>
    <description>Time to maximum plasma drug concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse events</measure>
    <time_frame>58 days</time_frame>
    <description>The incidence, type and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter sodium</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter potassium</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter calcium</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter glucose</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter urea</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter creatinine</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter total bilirubin</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter AST</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter ALT</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter gamma-glutamyl transferase</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline gamma-glutamyl transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter alkaline phosphatase</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter total protein</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter C-reactive protein</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter C-peptide</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Biochemistry laboratory parameter HbA1c</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Hematology laboratory parameter hemoglobin</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline hemglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Hematology laboratory parameter red blood cell count (erythrocytes)</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline red blood cell count (erythrocytes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Hematology laboratory parameter total white blood cell count (leukocytes)</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline total white blood cell count (leukocytes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Hematology laboratory parameter hematocrit</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Hematology laboratory parameter platelet count (thrombocytes)</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline platelet count (thrombocytes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Urinalysis laboratory parameter pH</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Urinalysis laboratory parameter blood</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Urinalysis laboratory parameter protein</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Urinalysis laboratory parameter glucose</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Urinalysis laboratory parameter ketones</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline ketones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Urinalysis laboratory parameter nitrite</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline nitrite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Summary of Local tolerability - Occurrence of incidents of injection site reactions</measure>
    <time_frame>28 days</time_frame>
    <description>Occurrence of incidents of injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Summary of Local tolerability - Summary of type of injection site reactions</measure>
    <time_frame>28 days</time_frame>
    <description>Summary of type of injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Summary of Local tolerability - Summary of severity of injection site reactions</measure>
    <time_frame>28 days</time_frame>
    <description>Summary of severity of injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of rescue infusions</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Number of rescue infusions of IV glucose after trial drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Time to first rescue infusion</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Time to first rescue infusion of IV glucose after trial drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Occurrence of anti-drug antibodies</measure>
    <time_frame>28 days</time_frame>
    <description>Occurrence of antibodies against dasiglucagon</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>dasiglucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single fixed dose (sc injection) of dasiglucagon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single fixed dose (sc injection) of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasiglucagon</intervention_name>
    <description>Glucagon analogue</description>
    <arm_group_label>dasiglucagon</arm_group_label>
    <other_name>ZP4207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for dasiglucagon</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for dasiglucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subjects with T1DM for at least 1 year; diagnostic criteria as defined
             by the American Diabetes Association (3).

          -  Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
             (defined as no more than a 10-unit daily variation in total daily insulin dose) 30
             days prior to screening

          -  Hemoglobin A1c &lt;10%.

          -  Aged between 18 and 75 years, both inclusive.

        Exclusion Criteria:

          -  Previous participation in a clinical trial within the dasiglucagon in the rescue
             treatment of hypoglycemia program.

          -  Known or suspected allergy to trial drug(s) or related products.

          -  History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).

          -  Previous participation in this trial. Participation being defined by signing the
             informed consent document.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lena S List</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <disposition_first_submitted>March 10, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 10, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 13, 2020</disposition_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

